Preparation of vaccines using photosensitizer and light
| Title: | Preparation of vaccines using photosensitizer and light |
|---|---|
| Patent Number: | 8,759,092 |
| Publication Date: | June 24, 2014 |
| Appl. No: | 12/869526 |
| Application Filed: | August 26, 2010 |
| Abstract: | Methods are provided for treating a vaccine containing infectious particles which may be viral, bacterial, and/or cellular in nature. Preferred methods include the steps of adding an effective, non-toxic amount of an endogenous photosensitizer to the fluid and exposing the fluid to photoradiation sufficient to inactivate the infectious particles but not enough to damage the antigenic characteristics of the infectious particles. |
| Inventors: | Goodrich, Raymond P. (Lakewood, CO, US) |
| Assignees: | Terumo BCT Biotechnologies, LLC (Lakewood, CO, US) |
| Claim: | 1. A method of making a composition comprising inactivated tumor cells, wherein the composition comprising the inactivated tumor cells is administered to a patient, the method comprising: removing a tumor from the patient; purifying at least some tumor cells from the tumor; containing the tumor cells in a photopermeable container for radiation; adding an endogenous photosensitizer to the photopermeable container, wherein the endogenous photosensitizer comprises 7,8-dimethyl-10-ribityl isoalloxazine, and wherein the endogenous photosensitizer is at a concentration of at least about 10 μM; inactivating the tumor cells by exposing the tumor cells to the endogenous photosensitizer and light at a sufficient wavelength to prevent replication of the tumor cells but not substantially destroy the antigenic determinants of the tumor cells, wherein the exposing comprises: irradiating the tumor cells and the endogenous photosensitizer in the photopermeable container at a range of between about 1 to about 120 J/cm 2 for a period of between about 6 to about 36 minutes; suspending the inactivated tumor cells in a suspension solution to make the composition comprising the inactivated tumor cells, wherein the suspension solution comprises one or more from the group consisting of: saline and water; and administering the composition comprising the inactivated tumor cells to the patient subcutaneously, intramuscularly, intraperitoneally, orally, or nasally. |
| Claim: | 2. The method of claim 1 , wherein the suspension solution comprises one or more from the group consisting of: an antibiotic and a preservative. |
| Claim: | 3. The method of claim 1 , wherein the suspension solution comprises an adjuvant. |
| Current U.S. Class: | 435/325 |
| Patent References Cited: | 3259546 July 1966 Polley 4402318 September 1983 Swartz 4545987 October 1985 Giles et al. 4556556 December 1985 Wiesehahn et al. 4693981 September 1987 Wiesehahn et al. 4915683 April 1990 Sieber 4960408 October 1990 Klainer et al. 5106619 April 1992 Wiesehahn et al. 5143717 September 1992 Davis 5462733 October 1995 Edelson et al. 5571666 November 1996 Floyd et al. 5686436 November 1997 Van Dyke 5846961 December 1998 Van Dyke 6165711 December 2000 Dorner et al. 6251644 June 2001 Sowemimo-Coker et al. 6258577 July 2001 Goodrich et al. 6268120 July 2001 Platz et al. 6831086 December 2004 Bernhardt 7049110 May 2006 Reddy et al. 7094378 August 2006 Goodrich et al. 7186543 March 2007 Goodrich 2004/0005712 January 2004 Platz 2004/0006028 January 2004 Platz 2004/0038373 February 2004 Platz et al. 19960706 June 2001 0124363 November 1984 0196515 October 1986 WO 00/04930 February 2000 WO 03/054150 July 2003 WO 03/095621 November 2003 WO 2004/043338 May 2004 |
| Other References: | Laucius et al., Cancer, 1977, 40:2091-2093. cited by examiner International Search Report for corresponding foreign application: PCT/US02/40923, filed Dec. 20, 2002, mailed Jul. 29, 2003. cited by applicant Baars et al, A phase II study of active specific immunotherapy and 5-FU/Leucovorin as adjuvant therapy for stage III colon carcinoma, British Journal of Cancer, 86(8):1230-1234, 2002. cited by applicant Balladur, Helene, “Photolysis of Riboflavin Induces Apoptosis in Epstein-Barr Virus Transformed Lymphoblastoid Cells: Design of a Cellular Vaccine for EBV-Associate Lymphoma”, Masters Thesis, Ohio State University, 2002, pp. 57-65. cited by applicant Dardare at al, “Binding Affinities of Commonly Employed Sensitizers of Viral Inactivation”, Photochemistry and Photobiology, 2002, 75(6): 561-564. cited by applicant Eertweigh ct al, Adjuvant treatment of colorectal cancer Towards tumor-specific immunotherapies, Cancer and Metastasis Reviews, 20:101-108, 2001. cited by applicant Vermorken et al, “Active specific immunotherapy for stage II and stage III human colon cancer: a randomized trial”, The Lancet, 353:345-50, 1999. cited by applicant Wagner et al, “Determination of Residual 4′-aminomethyl-4,5′,8-trimethylpsoralen and Mutagenicity Testing following Psoralen Plus UVA Treatment of Platelet Suspensions”, Photochemistry and Photobiology, vol. 57, No. 5, pp. 819-824, 1993. cited by applicant |
| Primary Examiner: | Chen, Stacy B. |
| Attorney, Agent or Firm: | Reagan, Elizabeth J. Merkling, John R. Pereyra, René A. |
| Accession Number: | edspgr.08759092 |
| Database: | USPTO Patent Grants |
| Language: | English |
|---|